Back to top
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Arcadia Biosciences, Inc. (RKDA) - free report >>
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Arcadia Biosciences, Inc. (RKDA) - free report >>
Image: Bigstock
New Strong Buy Stocks for October 17th
Here are five stocks added to the Zacks Rank #1 (Strong Buy) List today:
Manitex International, Inc. : This engineered lifting solutions company has seen the Zacks Consensus Estimate for its current year earnings increasing 63.6% over the last 60 days.
Manitex International, Inc. Price and Consensus
Manitex International, Inc. price-consensus-chart | Manitex International, Inc. Quote
Progyny, Inc. (PGNY - Free Report) : This benefits management company has seen the Zacks Consensus Estimate for its current year earnings increasing 6% over the last 60 days.
Progyny, Inc. Price and Consensus
Progyny, Inc. price-consensus-chart | Progyny, Inc. Quote
Griffon Corporation (GFF - Free Report) : This home and building products company has seen the Zacks Consensus Estimate for its current year earnings increasing 5.5% over the last 60 days.
Griffon Corporation Price and Consensus
Griffon Corporation price-consensus-chart | Griffon Corporation Quote
Arcadia Biosciences, Inc. (RKDA - Free Report) : This plant-based food and beverage company has seen the Zacks Consensus Estimate for its current year earnings increasing 47.5% over the last 60 days.
Arcadia Biosciences, Inc. Price and Consensus
Arcadia Biosciences, Inc. price-consensus-chart | Arcadia Biosciences, Inc. Quote
Cyclacel Pharmaceuticals, Inc. : This biopharmaceutical company has seen the Zacks Consensus Estimate for its current year earnings increasing 11.8% over the last 60 days.
Cyclacel Pharmaceuticals, Inc. Price and Consensus
Cyclacel Pharmaceuticals, Inc. price-consensus-chart | Cyclacel Pharmaceuticals, Inc. Quote
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.